All In MedTech

Device Trial Radar · NCT07908303

Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning

Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning: The WISE Study

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
First posted
Nov 2, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Stroke is a leading global cause of death and disability. In 2021 there were 11.9 million incident strokes (10.7-13.2 million) and 93.8 million prevalent stroke survivors (89.0-99.3 million) worldwide. The burden in China is particularly severe: stroke is the leading cause of disability-adjusted life years lost, at 45.9 million, and causes more than 2 million deaths each year. Recurrence is common after a first stroke, with reported recurrence rates ranging from 5.7% to 51.3%; approximately 7.7% of patients recur within 3 months and 10.4% within 12 months, and a cohort study of 500,000 Chinese adults found that 41% (95% CI 41%-42%) of stroke survivors had a recurrence at 5 years. Recurrent stroke is associated with higher mortality, greater disability and increased consumption of health care resources, making secondary prevention after stroke the core element of reducing recurrence and improving prognosis. Current stroke prevention and control systems remain largely reactive. Monitoring relies mainly on the patient's subjective perception after symptom onset, emergency response is triggered by telephone calls, and there is no mechanism for pre-symptomatic active sensing or active intervention at onset. The median onset-to-door time in China is still 180-240 minutes and reperfusion treatment rates (2.4%-7%) lag behind those of developed countries. Existing risk assessment tools such as the Framingham score are static models based on demographic characteristics; they cannot reflect the spatiotemporal evolution of physiological parameters in the 24-72 hours before onset and therefore cannot detect a 'recent high-risk state'. Digital health management is mostly one-way information push without bidirectional, agent-driven interaction, resulting in low patient adherence and warning messages that rarely translate into protective action. Wearable health-monitoring devices combined with agentic artificial intelligence offer continuous, real-time and quantifiable physiological monitoring in everyday life. However, the effectiveness, feasibility and safety of such warning and intervention systems for stroke patients, especially for secondary prevention after discharge, have not been systematically evaluated. This study therefore evaluates a stroke early-warning system based on wearable monitoring and clinical data fusion, in order to provide evidence for a digital management model for stroke prevention.

Conditions

  • Stroke
  • Ischemic Stroke
  • Recurrent Stroke
  • Transient Ischemic Attack
  • Intracerebral Haemorrhage
  • Subarachnoid Hemorrhage

Interventions

  • Huawei HAY20Device

    Continuous wearable physiological monitoring and AI-based stroke early warning - smart band (Huawei HAY20) worn continuously, monitoring heart rate, physical activity, sleep, blood oxygen and arrhythmia screening, with the companion mobile application and AI agent providing medication reminders, structured risk warnings and bidirectional interaction.

  • AI agent dialogueBehavioral

    Medication adherence management delivered by the system and the research team (automated reminders; proactive contact after three or more consecutive missed doses). Health education, lifestyle guidance and emotional support delivered through periodic bidirectional AI agent dialogue

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Stroke Events within 12 Months after EnrollmentTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.